< Terug naar vorige pagina
Berschermen SARS-CoV-2 specifieke antilichamen tegen herinfectie ? (ImmCoV)
The objectives of this study are (1) to determine the ex vivo neutralizing capacity and the longevity of SARS-CoV-2-specific Ab responses and (2) to measure the MBC responses in a cohort of health care workers (HCW) recovering from severe, mild or asymptomatic infection. By focusing on HCW, a population that is at risk for re-infection during a second epidemic wave, we also aim to correlate nAb levels with protection.
Datum:22 mei 2020 → Heden